FDA Clears Meridian Congenital Cytomegalovirus Assay
FDA has cleared a Meridian Bioscience 510(k) for its new Alethia CMV Molecular Amplification Test. This assay is designed to detect congenital cytomegalovirus (cCMV) infection in newborns from a saliva sample. It is the first qualitative test in a molecular amplification format cleared for cCMV testing in newborns, the company says. Congenital CMV is the most common congenital infection and a leading cause of childhood hearing loss, cognitive deficits, and visual impairment, it adds.